Automate Your Wheel Strategy on RPTX
With Tiblio's Option Bot, you can configure your own wheel strategy including RPTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RPTX
- Rev/Share -1.2304
- Book/Share 2.9371
- PB 0.4903
- Debt/Equity 0.011
- CurrentRatio 7.4154
- ROIC -1.0767
- MktCap 61763616.0
- FreeCF/Share -2.759
- PFCF -0.5256
- PE -0.4796
- Debt/Assets 0.0095
- DivYield 0
- ROE -0.7812
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Repare Therapeutics Inc. (RPTX)
- IPO Date 2020-06-19
- Website https://www.reparerx.com
- Industry Biotechnology
- CEO Steve Forte CPA
- Employees 129
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.